The socio-economic status (SES) of participants in many public health, epidemiological, and genome-wide association studies is an important trait of interest. It is often used in these studies as a measure of direct interest or as a covariate. There are open methodological issues on how SES is computed. The Africa Wits INDEPTH Partnership for Genomic and Environmental Research (AWI-Gen) explores genomic and environmental factors in non-communicable diseases, particularly cardio-metabolic disease. In Phase I of AWI-Gen, approximately 12,000 participants were recruited at six sites in four African countries. Participants were asked questions about asset ownership. This technical note describes how AWI-Gen computed socio-economic status from the asset register.

The authors have declared no competing interest.

The AWI-Gen Collaborative Centre is funded by the National Human Genome Research Institute (NHGRI), Office of the Director (OD), Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), the National Institute of Environmental Health Sciences (NIEHS), the Office of AIDS research (OAR) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), of the National Institutes of Health (NIH) under award number U54HG006938 and its supplements, as part of the H3Africa Consortium. The study was also partly funded the Department of Science and Innovation, South Africa, award number DST/CON 0056/2014, and by the African Partnership for Chronic Disease Research (APCDR).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Human Research (Medical) Ethics Committee of the University of the Witwatersrand, Johannesburg gave ethical approval for the AWI-Gen study (Protocol Numbers: M121029, M170880, M2210108). Each of the participating sites also obtained ethics approval from their respective ethics committees. AWI-Gen sample data was used as permitted by the informed consent provided by the study participants and according to the H3Africa policies and guidelines (www.h3africa.org).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

The AWI-Gen data set is available from the European Genome-phenome Archive (EGA) database (https://ega-archive.org/), with accession number EGAS00001002482 (phenotype dataset: EGAD00001006425). The availability of these datasets is subject to controlled access through the Data and Biospecimen Access Committee of the H3Africa Consortium.